Benjamin Stordy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Benjamin Stordy has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Warren C. W. Chan
Institute of Biomedical Engineering, University of Toronto, Rosebrugh Building, 164 College Street, Toronto, Ontario M5S 3G9, Canada
7 shared publications Zahra Sepahi
Institute of Biomedical Engineering
4 shared publications- Bill Ling
Division of Chemistry and Chemical Engineering, California Institute of Technology
3 shared publications - Mikhail G. Shapiro
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, USA
3 shared publications - Wayne Ngo
Innovative Genomics Institute, University of California, Berkeley, Berkeley, USA
3 shared publications Yuwei Zhang
Institute of Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada
3 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Small Data at Small Scales: Learning Nanoparticle Affinities from Sparse Physicochemical Datasets
However, serum proteins bind to nanoparticle surfaces, changing how they interact with on-and off-target cells. Nanoparticles have a vast design space spanning continuous and categorical design features, including size, material, charge, and surface ligands. In this work, we study representations of nanoparticle physicochemical properties to enable Gaussian Processes and Prior-Data Fitted Networks to predict the serum protein binding affinity of nanoparticles. These models represent the first data-driven approaches to predicting serum protein-nanoparticle affinities. Despite scarce data (≈ 250 data points), the models generalize to unseen nanoparticle designs with moderate predictive accuracy (R2 ≈ 0.50) and strong ranking performance (Spearman’s ρ ≈ 0.73). Because experimental design depends on correctly prioritizing candidates rather than on exact prediction, the latter is a key measure of practical utility. Our work demonstrates that predictive models trained on small but systematically measured datasets may enable model-guided exploration of nanoparticle design properties, reducing the experimental burden of navigating a large design space.
- 30 July 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessSmall Data at Small Scales: Learning Nanoparticle Affinities from Sparse Physicochemical Datasets
However, serum proteins bind to nanoparticle surfaces, changing how they interact with on-and off-target cells. Nanoparticles have a vast design space spanning continuous and categorical design features, including size, material, charge, and surface ligands. In this work, we study representations of nanoparticle physicochemical properties to enable Gaussian Processes and Prior-Data Fitted Networks to predict the serum protein binding affinity of nanoparticles. These models represent the first data-driven approaches to predicting serum protein-nanoparticle affinities. Despite scarce data (≈ 250 data points), the models generalize to unseen nanoparticle designs with moderate predictive accuracy (R2 ≈ 0.50) and strong ranking performance (Spearman’s ρ ≈ 0.73). Because experimental design depends on correctly prioritizing candidates rather than on exact prediction, the latter is a key measure of practical utility. Our work demonstrates that predictive models trained on small but systematically measured datasets may enable model-guided exploration of nanoparticle design properties, reducing the experimental burden of navigating a large design space.
- 9 June 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (24) , 20475-20492
The Binding Affinities of Serum Proteins to Nanoparticles
Nanoparticles can be coated with targeting ligands to deliver medical agents to specific cells. Serum protein adsorption affects the binding of nanoparticles to target cells. We hypothesized that serum proteins and target receptors compete for binding to nanoparticles. We tested the serum protein binding affinity of 251 nanoparticle designs. Here, we discovered that the binding affinities of serum proteins and receptors to a nanoparticle determine whether it can bind to target cells. We developed and validated a quantitative metric, the binding ratio, to identify nanoparticle designs that can bind to targets in serum with 90% sensitivity and 88% specificity. Using the binding ratio as a numerical guideline for nanoparticle design enabled us to improve the efficiency of nanoparticle binding to target cellular receptors.
- 9 June 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (24) , 20475-20492
The Binding Affinities of Serum Proteins to Nanoparticles
Nanoparticles can be coated with targeting ligands to deliver medical agents to specific cells. Serum protein adsorption affects the binding of nanoparticles to target cells. We hypothesized that serum proteins and target receptors compete for binding to nanoparticles. We tested the serum protein binding affinity of 251 nanoparticle designs. Here, we discovered that the binding affinities of serum proteins and receptors to a nanoparticle determine whether it can bind to target cells. We developed and validated a quantitative metric, the binding ratio, to identify nanoparticle designs that can bind to targets in serum with 90% sensitivity and 88% specificity. Using the binding ratio as a numerical guideline for nanoparticle design enabled us to improve the efficiency of nanoparticle binding to target cellular receptors.
- Top Cited Papers
- 15 May 2025
- Published by Springer Nature in Nature Nanotechnology
- Vol. 20 (7) , 914-925
Discovering nanoparticle corona ligands for liver macrophage capture
Liver macrophages capture circulating nanoparticles and reduce their delivery to target organs. Serum proteins adsorb to the nanoparticle surface after administration. However, the adsorbed serum proteins and their cognate cell receptors for removing nanoparticles from the bloodstream have not been linked. Here we use a multi-omics strategy to identify the adsorbed serum proteins binding to specific liver macrophage receptors. We discovered six absorbed serum proteins that bind to two liver macrophage receptors. Nanoparticle physicochemical properties can affect the degree of the six serum proteins adsorbing to the surface, the probability of binding to cell receptors and whether the liver removes the nanoparticle from circulation. Identifying the six adsorbed proteins allowed us to engineer decoy nanoparticles that prime the liver to take up fewer therapeutic nanoparticles, enabling more nanoparticles for targeting extrahepatic tissues. Elucidating the molecular interactions governing the nanoparticle journey in vivo will enable us to control nanoparticle delivery to diseased tissues.
- 15 May 2025
- Published by Springer Nature in Nature Nanotechnology
- Vol. 20 (7) , 914-925
Top Cited PapersDiscovering nanoparticle corona ligands for liver macrophage capture
Liver macrophages capture circulating nanoparticles and reduce their delivery to target organs. Serum proteins adsorb to the nanoparticle surface after administration. However, the adsorbed serum proteins and their cognate cell receptors for removing nanoparticles from the bloodstream have not been linked. Here we use a multi-omics strategy to identify the adsorbed serum proteins binding to specific liver macrophage receptors. We discovered six absorbed serum proteins that bind to two liver macrophage receptors. Nanoparticle physicochemical properties can affect the degree of the six serum proteins adsorbing to the surface, the probability of binding to cell receptors and whether the liver removes the nanoparticle from circulation. Identifying the six adsorbed proteins allowed us to engineer decoy nanoparticles that prime the liver to take up fewer therapeutic nanoparticles, enabling more nanoparticles for targeting extrahepatic tissues. Elucidating the molecular interactions governing the nanoparticle journey in vivo will enable us to control nanoparticle delivery to diseased tissues.
- Top Cited Papers
- 17 March 2025
- Published by Springer Nature in Nature Nanotechnology
- Vol. 20 (5) , 672-682
The pathways for nanoparticle transport across tumour endothelium
The active transport and retention principle is an alternative mechanism to the enhanced permeability and retention effect for explaining nanoparticle tumour delivery. It postulates that nanoparticles actively transport across tumour endothelial cells instead of passively moving through gaps between these cells. How nanoparticles transport across tumour endothelial cells remains unknown. Here we show that nanoparticles cross tumour endothelial cells predominantly using the non-receptor-based macropinocytosis pathway. We discovered that tumour endothelial cell membrane ruffles capture circulating nanoparticles, internalize them in intracellular vesicles and release them into the tumour interstitium. Tumour endothelial cells have a higher membrane ruffle density than healthy endothelium, which may partially explain the elevated nanoparticle tumour accumulation. Receptor-based endocytosis pathways such as clathrin-mediated endocytosis contribute to nanoparticle transport to a lesser extent. Nanoparticle size determines the degree of contribution for each pathway. Elucidating the nanoparticle transport mechanism is crucial for developing strategies to control nanoparticle tumour delivery.
- 17 March 2025
- Published by Springer Nature in Nature Nanotechnology
- Vol. 20 (5) , 672-682
Top Cited PapersThe pathways for nanoparticle transport across tumour endothelium
The active transport and retention principle is an alternative mechanism to the enhanced permeability and retention effect for explaining nanoparticle tumour delivery. It postulates that nanoparticles actively transport across tumour endothelial cells instead of passively moving through gaps between these cells. How nanoparticles transport across tumour endothelial cells remains unknown. Here we show that nanoparticles cross tumour endothelial cells predominantly using the non-receptor-based macropinocytosis pathway. We discovered that tumour endothelial cell membrane ruffles capture circulating nanoparticles, internalize them in intracellular vesicles and release them into the tumour interstitium. Tumour endothelial cells have a higher membrane ruffle density than healthy endothelium, which may partially explain the elevated nanoparticle tumour accumulation. Receptor-based endocytosis pathways such as clathrin-mediated endocytosis contribute to nanoparticle transport to a lesser extent. Nanoparticle size determines the degree of contribution for each pathway. Elucidating the nanoparticle transport mechanism is crucial for developing strategies to control nanoparticle tumour delivery.
- Open Access
- 20 November 2023
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 23 (23) , 10748-10757
Gas Vesicle–Blood Interactions Enhance Ultrasound Imaging Contrast
Gas vesicles (GVs) are genetically encoded, air-filled protein nanostructures of broad interest for biomedical research and clinical applications, acting as imaging and therapeutic agents for ultrasound, magnetic resonance, and optical techniques. However, the biomedical applications of GVs as systemically injectable nanomaterials have been hindered by a lack of understanding of GVs' interactions with blood components, which can significantly impact in vivo behavior. Here, we investigate the dynamics of GVs in the bloodstream using a combination of ultrasound and optical imaging, surface functionalization, flow cytometry, and mass spectrometry. We find that erythrocytes and serum proteins bind to GVs and shape their acoustic response, circulation time, and immunogenicity. We show that by modifying the GV surface we can alter these interactions and thereby modify GVs' in vivo performance. These results provide critical insights for the development of GVs as agents for nanomedicine.
- 20 November 2023
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 23 (23) , 10748-10757
Open AccessGas Vesicle–Blood Interactions Enhance Ultrasound Imaging Contrast
Gas vesicles (GVs) are genetically encoded, air-filled protein nanostructures of broad interest for biomedical research and clinical applications, acting as imaging and therapeutic agents for ultrasound, magnetic resonance, and optical techniques. However, the biomedical applications of GVs as systemically injectable nanomaterials have been hindered by a lack of understanding of GVs' interactions with blood components, which can significantly impact in vivo behavior. Here, we investigate the dynamics of GVs in the bloodstream using a combination of ultrasound and optical imaging, surface functionalization, flow cytometry, and mass spectrometry. We find that erythrocytes and serum proteins bind to GVs and shape their acoustic response, circulation time, and immunogenicity. We show that by modifying the GV surface we can alter these interactions and thereby modify GVs' in vivo performance. These results provide critical insights for the development of GVs as agents for nanomedicine.
- Top Cited Papers
- 17 August 2023
- Published by Springer Nature in Nature Materials
- Vol. 22 (10) , 1261-1272
The exit of nanoparticles from solid tumours
Nanoparticles enter tumours through endothelial cells, gaps or other mechanisms, but how they exit is unclear. The current paradigm states that collapsed tumour lymphatic vessels impair the exit of nanoparticles and lead to enhanced retention. Here we show that nanoparticles exit the tumour through the lymphatic vessels within or surrounding the tumour. The dominant lymphatic exit mechanism depends on the nanoparticle size. Nanoparticles that exit the tumour through the lymphatics are returned to the blood system, allowing them to recirculate and interact with the tumour in another pass. Our results enable us to define a mechanism of nanoparticle delivery to solid tumours alternative to the enhanced permeability and retention effect. We call this mechanism the active transport and retention principle. This delivery principle provides a new framework to engineer nanomedicines for cancer treatment and detection.
- 17 August 2023
- Published by Springer Nature in Nature Materials
- Vol. 22 (10) , 1261-1272
Top Cited PapersThe exit of nanoparticles from solid tumours
Nanoparticles enter tumours through endothelial cells, gaps or other mechanisms, but how they exit is unclear. The current paradigm states that collapsed tumour lymphatic vessels impair the exit of nanoparticles and lead to enhanced retention. Here we show that nanoparticles exit the tumour through the lymphatic vessels within or surrounding the tumour. The dominant lymphatic exit mechanism depends on the nanoparticle size. Nanoparticles that exit the tumour through the lymphatics are returned to the blood system, allowing them to recirculate and interact with the tumour in another pass. Our results enable us to define a mechanism of nanoparticle delivery to solid tumours alternative to the enhanced permeability and retention effect. We call this mechanism the active transport and retention principle. This delivery principle provides a new framework to engineer nanomedicines for cancer treatment and detection.
- Open Access
Gas vesicle-blood interactions enhance ultrasound imaging contrast
Gas vesicles (GVs) are genetically encoded, air-filled protein nanostructures of broad interest for biomedical research and clinical applications, acting as imaging and therapeutic agents for ultrasound, magnetic resonance, and optical techniques. However, the biomedical applications of GVs as a systemically injectable nanomaterial have been hindered by a lack of understanding of GVs’ interactions with blood components, which can significantly impact in vivo performance. Here, we investigate the dynamics of GVs in the bloodstream using a combination of ultrasound and optical imaging, surface functionalization, flow cytometry, and mass spectrometry. We find that erythrocytes and serum proteins bind to GVs and shape their acoustic response, circulation time, and immunogenicity. We show that by modifying the GV surface, we can alter these interactions and thereby modify GVs’ in vivo performance. These results provide critical insights for the development of GVs as agents for nanomedicine.
Open AccessGas vesicle-blood interactions enhance ultrasound imaging contrast
Gas vesicles (GVs) are genetically encoded, air-filled protein nanostructures of broad interest for biomedical research and clinical applications, acting as imaging and therapeutic agents for ultrasound, magnetic resonance, and optical techniques. However, the biomedical applications of GVs as a systemically injectable nanomaterial have been hindered by a lack of understanding of GVs’ interactions with blood components, which can significantly impact in vivo performance. Here, we investigate the dynamics of GVs in the bloodstream using a combination of ultrasound and optical imaging, surface functionalization, flow cytometry, and mass spectrometry. We find that erythrocytes and serum proteins bind to GVs and shape their acoustic response, circulation time, and immunogenicity. We show that by modifying the GV surface, we can alter these interactions and thereby modify GVs’ in vivo performance. These results provide critical insights for the development of GVs as agents for nanomedicine.
- 27 July 2022
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 34 (15) , 6868-6882
Conjugating Ligands to an Equilibrated Nanoparticle Protein Corona Enables Cell Targeting in Serum
- 27 July 2022
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 34 (15) , 6868-6882
Conjugating Ligands to an Equilibrated Nanoparticle Protein Corona Enables Cell Targeting in Serum